JPRN-jRCT2080221051未知3 期
Safety and efficacy of AIN457 in patients with active non-infectious uveitis
ovartis Pharma K.K.0 个研究点目标入组 208 人开始时间: 2010年3月31日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 208
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Male and female subjects 18 years of age or older
- •- Patients with diagnosis of chronic non-infectious intermediate uveitis, posterior uveitis or panuveitis in at least one eye
- •- Evidence of active intermediate, posterior or panuveitis at screening and baseline in at least one eye
- •- Requirement for any of the immunosuppressive therapies for the treatment or prevention of uveitis
排除标准
- •- Patients with a primary diagnosis of Behcet's disease or anterior uveitis
- •- Any intermediate uveitis, posterior uveitis or panuveitis in which the manifestation(s) of the active intraocular inflammatory disease may spontaneously resolve or that are not characterized by the presence of either anterior chamber cells or vitritis such as the white dot retino-choroidopathies
- •- Patients with infectious uveitis
研究者
相似试验
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with Chronic Back PaiChronic back painCTIS2022-502151-54-00Cannaxan GmbH558
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any GenesisChronic pain due to central Neuropathy of any GenesisCTIS2022-500899-66-00Cannaxan GmbH558
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic PolyneuropathyChronic pain due to diabetic polyneuropathyCTIS2022-500897-32-00Cannaxan GmbH558
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral NeuropathyChronic Pain due to traumatic or post-operative peripheral NeuropathyCTIS2022-500898-13-00Cannaxan GmbH558
未知
2 期
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type PsoriasispsoriasisJPRN-jRCT2080221043ovartis Pharma K.K.